A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma

BACKGROUND AND OBJECTIVE: For patients with advanced hepatocellular carcinoma (HCC), the standard of care for many years has been sorafenib. Preliminary data have suggested that the combination of the NAD(P)H:quinone oxidoreductase 1 bioactivatable agent napabucasin plus sorafenib may improve clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Okusaka, Takuji, Morimoto, Manabu, Eguchi, Yuichiro, Nakamura, Shinichiro, Iino, Shuichi, Kageyama, Rie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293504/
https://www.ncbi.nlm.nih.gov/pubmed/37188895
http://dx.doi.org/10.1007/s40268-023-00416-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293504/
https://www.ncbi.nlm.nih.gov/pubmed/37188895
http://dx.doi.org/10.1007/s40268-023-00416-8

Ejemplares similares